Treatment strategies of recurrent hepatitis C after liver transplantation based on IL28B singlencleotide polymorphism.

在日本进行了一项关于丙型肝炎病毒阳性受体活体肝移植（LDLT）的全国性调查。在这项研究中收集的514名受体中，361名患者在肝移植后接受了抗病毒治疗。VR率64.1%，SVR率38.3%。有SVR的5年和10年累积生存率（94.1%和83.0%）显著优于无SVR的患者（79.7%和60.8%）。主要等位基因（TT）在受体和供体中的存在对应的SVR为58.2%。次要等位基因（TG或GG）在受体或供体中的存在对应的SVR分别为15.7%、16.7%和28.5%。多因素分析显示，受体或供体中IL28B基因型多态性是实现SVR的独立因素。总之，我们的研究表明，供体和受体的IL28B基因型与移植存活和对IFN/RBV治疗的反应密切相关。

A nationwide survey of living donor liver transplantation (LDLT) for hepatitis C virus-positive recipients was performed in Japan. Of 514 recipients collected in the study, 361 patients underwent antiviral treatment after liver transplantation. VR rate was 64.1%, and SVR rate was 38.3%. The 5-yr and 10-yr cumulative patient survival with SVR (94.1% and 83.0%) were significantly superior than those without SVR (79.7% and 60.8%). Presence of the major allele (TT) in both the recipient and the donor corresponded to SVR of 58.2%. Presence of the minor allele (TG or GG) in either the recipient or the donor corresponded to SVR of 15.7%, 16.7% and 28.5%. Multivariate analysis revealed that genotype of IL28B polymorphisms in either the recipient or donor was an independent factor for achieving SVR. In conclusion, our study demonstrated that both donor and recipient IL28B genotype were strongly associated with graft survival and response to IFN/RBV therapy for LDLT recipients.